Global Orally Disintegrating Tablets Market Size By Type (Anti-Psychotics Drug, Anti-Epileptics Drug), By Application (CNS Diseases, Gastrointestinal Diseases), By Region, And Segment Forecasts, 2023...

The Global Orally Disintegrating Tablets (ODTs) Market was valued at USD 10.4 billion in 2023 and is projected to reach USD 18.9 billion by 2031, expanding at a CAGR of 7.6% during the forecast period of 2023–2031. The growth of the ODT market is fueled by the increasing demand for patient-friendly dosage forms, especially among pediatric and geriatric populations. ODTs offer rapid disintegration without water, enhancing compliance among patients with swallowing difficulties. The rising prevalence of neurological and psychiatric disorders, where ODT formulations are commonly prescribed, is also driving market expansion.

Drivers

1. Patient Compliance and Convenience:

ODTs significantly improve patient adherence, especially in populations such as children, the elderly, and individuals with dysphagia. The convenience of administration without the need for water makes them a preferred choice in outpatient and emergency settings.

2. Rising Prevalence of Chronic and Neurological Disorders:

Conditions such as schizophrenia, epilepsy, and migraines often require fast-acting formulations. ODTs enable quick onset of action and are commonly used in these therapeutic areas.

3. Advancements in Drug Formulation Technologies:

Improved excipient compatibility, taste-masking technologies, and patented manufacturing techniques are allowing more APIs to be developed in ODT form, expanding the therapeutic scope of these formulations.

Restraints

1. Limited Drug Load and Taste-Masking Challenges:

ODTs are not suitable for high-dose formulations, limiting their application for drugs that require large amounts. Additionally, ensuring palatability through taste-masking increases formulation complexity and cost.

2. Sensitivity to Moisture and Packaging Requirements:

ODTs are moisture-sensitive, requiring specialized packaging to ensure product stability, which adds to production and logistics costs, especially in humid climates.

Opportunity

1. Expansion in Emerging Economies and Telemedicine:

Growing healthcare access in emerging markets and the rise of telemedicine are contributing to increased demand for user-friendly dosage forms like ODTs. These markets represent untapped potential for pharmaceutical companies.

2. Pediatric and Geriatric Formulations:

The expanding aging population and global focus on pediatric drug development present lucrative opportunities. Regulatory encouragement for pediatric-specific dosage forms is also supporting the market.

Market by System Type Insights

Fast-Melt Tablets dominated the market in 2023 due to their ease of use, patient acceptability, and effectiveness in delivering a rapid onset of action. This segment is expected to maintain its leadership through 2031, driven by continuous innovation in formulation science and a broadening range of applications in acute and chronic conditions.

Market by End-use Insights

Hospital Pharmacies accounted for the largest revenue share in 2023, owing to the frequent use of ODTs for acute interventions and the management of chronic conditions. Retail Pharmacies are projected to witness robust growth due to increasing over-the-counter (OTC) availability of ODTs for conditions like allergies, pain, and gastrointestinal disorders.

Market by Regional Insights

North America held the largest market share in 2023, attributed to advanced healthcare infrastructure, high adoption of innovative drug delivery systems, and strong presence of key pharmaceutical players. Asia-Pacific is expected to register the fastest growth, driven by increasing healthcare awareness, large target population, and improving access to pharmaceuticals in countries such as China and India.

Competitive Scenario

Major companies in the global ODT market include Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Catalent, Inc., Bayer AG, Mylan N.V., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., and GlaxoSmithKline plc. Strategic collaborations, R&D investments, and new product launches are the core strategies adopted by these players.

In 2024, Catalent, Inc. expanded its ODT manufacturing capabilities with a new facility in the U.S., enhancing supply chain reliability.

Pfizer Inc. introduced a pediatric ODT version of its popular antihistamine in 2023, aiming to increase compliance among children.

Teva Pharmaceutical announced an R&D collaboration in 2025 to develop next-generation ODTs with enhanced taste-masking technologies.

Scope of Work – Global Orally Disintegrating Tablets Market

Key Market Developments

2024: Novartis launched a migraine ODT therapy with rapid onset properties targeting adult patients.

2023: GlaxoSmithKline received FDA approval for a new ODT formulation of a pediatric antihistamine.

2025: Dr. Reddy’s Laboratories announced a strategic partnership to introduce low-cost ODTs in Southeast Asia.

FAQs

What is the current market size of the Global Orally Disintegrating Tablets Market?

The market was valued at USD 10.4 billion in 2023.

What is the major growth driver of the Global Orally Disintegrating Tablets Market?

The key growth driver is increased patient compliance, especially among pediatric and geriatric populations.

Which is the largest region during the forecast period in the Global Orally Disintegrating Tablets Market?

North America dominated the market in 2023 and is expected to retain its lead.

Which segment accounted for the largest market share in the Global Orally Disintegrating Tablets Market?

Fast-Melt Tablets led the market by system type in 2023.

Who are the key market players in the Global Orally Disintegrating Tablets Market?

Key players include Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Catalent, Inc., and Bayer AG.